LANGUAGE
KOREANENGLISH
LOCATION
  • COMPANY
  • R&D
    • R&D Institute
    • GMP Manufacturing Facility
    • Clinical Development Status
    • Publications
  • PRODUCTS
    • 1st Generation
      • Overview
      • CARTISTEM®
      • PNEUMOSTEM®
    • 2nd Generation
      • Overview
      • SMUP-IA-01
      • SMUP-IV-01
    • R&D Inquiries
  • BUSINESS
    • CDMO
      • Quality System
      • CDMO Service
      • Quality Control
      • Global CDMO
      • CDMO Inquiries
    • CELLTREE Cord Blood Bank
    • MOVITA Nutritional Supplements
  • IR
    • Stock Information
    • Disclosure
    • Financial Information
    • IR Inquiries
  • PR
    • MEDIPOST on Media
    • Corporate Brochure
  • CONTACT US
    • Customer Center
    • R&D Inquiries
    • CDMO Inquiries
    • IR Inquiries
MEDIPOST, selected as a “Excellent Disclosure Corporation” by the Korea Exchange
2018/04/18
MEDIPOST

– Transparent management and sincere disclosure, attaining fruitful efforts for investors

MEDIPOST announced on April 18 that it was selected as an ‘Excellent Disclosure Corporation’ by the Korea Exchange.

The “Excellent Corporation” is an award given to companies that have contributed to enhancing the transparency of listed companies and creating a climate of sincerity for investors, and the Korea Exchange has been performing the selection since 2012.

MEDIPOST is known for its high praise in terms of the accuracy of disclosures, an understanding of the law enforcement officials, the construction of disclosure infrastructures, voluntary disclosures, and corporate presentations.

With this award, MEDIPOST will receive a wide range of benefits and acts of convenience from the Korea Exchange for the next three years, including the suspension of the designation of unfaithful disclosure corporations, the exemption from the preliminary confirmation of disclosure contents, and annual training exemption.

In addition, the public officials of the “Excellent Corporation” will receive a separate commendation as a “Public Man of Merit”. MEDIPOST is undertaken with various responsibilities, headed by President Hwang Dong Jin, Jeon Gyo Jong, the Head of Finance, and Lee Hwa Young, Head of the IR Team.

In this regard, Lee Hwa Young, head of the IR team of MEDIPOST, said, “We will strive to improve the value of the company through always providing sincere disclosure and transparent and fair information to our investors.”

VIEW LIST

Related News

MEDIPOST Selected as Outstanding Taxpayer2016/03/04

Latest News

MEDIPOST Enhances its Partnership with Canada’s OmniaBio in Collaboration for the CMDO Business of OmniaBio’s All-Around Cell and Gene Therapy.
2022/12/01
Medipost to launch a CDMO business for cell and gene therapy products in Korea based on 20 years of research and production knowledge
2022/10/17
Canada’s OmniaBio, MEDIPOST affiliate begins CDMO cGMP for cell gene therapy
2022/10/07
MEDIPOST’s 5-year follow-up of phase 3 clinical trial patients receives 2021 OJSM award
2022/07/18
Medipost enters North American market by acquiring OmniaBio, a CDMO company with cell and gene therapy products
2022/05/31

Contacts

21, Daewangpangyo-ro 644, Bundang-gu, Seongnam-si, Gyeonggi-do, Korea MEDIPOST Co., Ltd.
TEL : 82-2-3465-6677

CS CENTER
ONLINE INQUIRY

Latest News

·
MEDIPOST Enhances its Partnership with Canada’s OmniaBio in Collaboration for the CMDO Business of OmniaBio’s All-Around Cell and Gene Therapy.2022.12.01
·
Medipost to launch a CDMO business for cell and gene therapy products in Korea based on 20 years of research and production knowledge2022.10.17
·
Canada’s OmniaBio, MEDIPOST affiliate begins CDMO cGMP for cell gene therapy2022.10.07
·
MEDIPOST’s 5-year follow-up of phase 3 clinical trial patients receives 2021 OJSM award2022.07.18
·
Medipost enters North American market by acquiring OmniaBio, a CDMO company with cell and gene therapy products2022.05.31

Family Site

· CELLTREE Cord Blood Bank
· MOVITA Nutritional Supplements

· LOCATION
· PRIVACY POLICY

©Copyright – The Future of Biotechnology, MEDIPOST